Navigation Links
Vasogen Announces 2007 Year-End Results
Date:1/16/2008

ance of our products, the availability of government and insurance reimbursements for our products, the strength of intellectual property, reliance on partners, subcontractors, and key personnel, losses due to fluctuations in the U.S.-Canadian exchange rate, and other risks detailed from time to time in our public disclosure documents or other filings with the Canadian and U.S. securities commissions or other securities regulatory bodies. Additional risks and uncertainties relating to our Company and our business can be found in the "Risk Factors" section of our Annual Information Form and Form 20-F for the year ended November 30, 2006, as well as in our later public filings. The forward-looking statements are made as of the date hereof, and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

The consolidated financial statements, accompanying notes to the consolidated financial statements, and Management's Discussion and Analysis for the year ended November 30, 2007, will be accessible on Vasogen's web site at http://www.vasogen.com and will be available on SEDAR and EDGAR.

Financial statements are provided below.

VASOGEN INC.

(A DEVELOPMENT STAGE COMPANY)

Consolidated Balance Sheets

(In thousands of Canadian dollars)

November 30, 2007 and 2006

-------------------------------------------------------------------------

2007 2006

-------------------------------------------------------------------------

Assets

Current assets:

Cash and cash equivalents $ 23,545 $ 30,427

Restricted cash - 6,403

Clinica
'/>"/>

SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
9. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... regenerative medicine, today announced that it will release fourth ... on Tuesday, March 10, 2015 after the close of ... conference call and webcast on Tuesday, March 10, 2015 ... discuss the results and recent corporate developments. ...
(Date:3/2/2015)... 2015 Global Stem Cells ... with Shenzhen HANK Bioengineering Co., Ltd. and its ... will establish a stem cells training course in ... September 2015. , Shenzhen HANK is a biotechnology ... scientist, microbiologist and virologist, to integrate research, development, ...
(Date:2/28/2015)... Increasing its efforts to resolve the GMO ... episodes of The GMO TRUTH podcast on both ITunes and ... continues its mission to discover the truth and change the ... “uncover the truth about the GMOs in our food supply,” ... Podcast is an expansion of the documentary/investigative film-making methodology in ...
(Date:2/27/2015)... 2015  Pharmacyclics, Inc. (NASDAQ: PCYC ... its newly developed Bruton,s tyrosine kinase (BTK) inhibitor ... The results of these preclinical evaluations have been ... The feedback received from the Agency is supportive ... Additional preclinical work is required to begin a ...
Breaking Biology Technology:Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2014 Results on March 10, 2015 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 3The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3
... , , LOS ANGELES, Aug. 6 ... an 82 year-old Chinese female immigrant who suffered Stevens-Johnson Syndrome/Toxic Epidermal ... Defendant, an osteopathic physician and registered pharmacist, prescribed it to her ... did not have gout. The doctor claimed that she told ...
... , , OMAHA, Neb., Aug. 6 Transgenomic Inc. (OTC ... What: Transgenomic Inc. Second Quarter 2009 Earnings Release, ... Wednesday, August 12, 2009 @ 5:00 p.m. Eastern, Where: ... the Internet -- Simply log on to the web at the, ...
... , , , , ... drugs to combat Alzheimer,s began journey 8 years ago , , ... of a million" , , NEW YORK, Aug. 6 ... (ADDF) , have achieved a significant milestone in their development as they advance ...
Cached Biology Technology:The Law Offices of Brian D. Witzer Wins 6+ Million Dollar Verdict 2Webcast Alert: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast 2PharmatrophiX, Initially Funded by the Alzheimer's Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan 2PharmatrophiX, Initially Funded by the Alzheimer's Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan 3
(Date:2/23/2015)... , Feb. 23, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... filed provisional patent 62114357 for DISTRIBUTED VOICE ... patent, NXT-ID introduces a new groundbreaking payment method. Payment ... payment account may only be accessed if both the ...
(Date:2/12/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announced ... DISTRIBUTED METHOD AND SYSTEM TO IMPROVE COLLABORATIVE ... establishes NXT-ID,s position in the emerging "Internet of Things" ... for multiple devices to collaborate with one another to ...
(Date:2/5/2015)... , Feb. 5, 2015  Marken is starting ... company and has launched a new marketing campaign to ... Organization (CLO).  The new campaign focuses on First ... protocol and shipments. The first headline in ... aligns Marken,s priorities with its client,s priorities. Marken recognizes ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken Launches New Patient-Centric Campaign 2
... surrounds the DNA of our cells could help develop treatments ... have discovered that the proteins within this coating known ... different organs of the body. This variation ... proteins in the protective seal to cause illness in some ...
... Daejeon, Republic of Korea, February 26, 2013The Korea Advanced ... a global energy and petrochemicals enterprise, signed on February ... Agreement) on joint collaborations in research and development of ... Agreement was subsequently concluded upon the signing of the ...
... is faced with some of the world,s worst pollution. Until ... a major contributor to that pollution human-caused nitrogen emissions ... biology professor and Stanford Woods Institute senior fellow Peter Vitousek ... deposited on land and water in China by way of ...
Cached Biology News:Cell discovery could hold key to causes of inherited diseases 2Launched the Saudi Aramco-KAIST CO2 Management Center in Korea 2Stanford scientists help shed light on key component of China's pollution problem 2
For relative and/or absolute quantification with standard accuracy requirements using MS or NMR instruments...
PxE thermal Cycler. 0.5ml block holds 48 0.5 ml tubes or 96 0.3 ml tubes. Adjustable height heated lid. Outstanding uniformity. Advanced control algorithms for reduced reaction times. User frien...
For testing the AQUA technique on your MS instruments....
0.2ml Gradient Block MBSR. Robot compatible block ejection mechanism. Stackable. (96 well block - holds 1 plate 0.2ml x 96 well plate)...
Biology Products: